Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | PTAFR | P25105 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795746 | 0.88 | TDP1 (0.65) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL769818 | 0.88 | CHRNA7 (0.53) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL28594585 | 0.84 | TDP1 (0.59) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL23795734 | 0.84 | TDP1 (0.59) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL29485675 | 0.82 | TDP1 (0.80) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL724788 | 0.82 | TDP1 (0.80) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL2845851 | 0.80 | HRH1 (0.81) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL29485667 | 0.80 | HRH1 (0.81) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL29485634 | 0.80 | HRH1 (0.81) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 | |
| SCHEMBL8658187 | 0.80 | HRH1 (0.81) | TBXAS1TDP1L3MBTL1HRH1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-2650283-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2141149-B1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2650282-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650283-A1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| CN-102643170-A | Method for synthesizing para-tert-butylcatechol by using acid-mixed mixed system containing ionic liquid | UNIV HEBEI TECHNOLOGY | 2012-08-22 | — | — | CN | disclosed |
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2141149-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | Nippon Soda Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071656-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | TBXAS1 2484/4885TDP1 2041/4885L3MBTL1 1877/4885 |
| US-20140323724-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | TBXAS1 2484/4885TDP1 2041/4885L3MBTL1 1877/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | TBXAS1 1002/4885TDP1 1197/4885L3MBTL1 4124/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | TBXAS1 788/4885TDP1 326/4885L3MBTL1 2776/4885 |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | TBXAS1 2484/4885TDP1 2041/4885L3MBTL1 1877/4885 |
| US-20100121054-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | TBXAS1 2208/4885TDP1 2615/4885L3MBTL1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.